LoQus23 Therapeutics

LoQus23 Therapeutics is a private, preclinical-stage biotech targeting a novel mechanism in repeat expansion disorders like Huntington's disease. The company, founded by experienced industry veterans, is developing small molecules designed to inhibit somatic expansion of DNA repeats, aiming to halt disease progression at its source. Backed by the Dementia Discovery Fund and led by a team with deep neuroscience and drug discovery expertise, LoQus23 is positioned to address a high-unmet medical need with a potentially disease-modifying approach.

Small molecule somatic expansion inhibitors targeting DNA repeat instability in triplet repeat disorders.

LoQus23 competes in the Huntington's disease space against companies developing antisense oligonucleotides (e.g., Roche/Ionis, Wave Life Sciences), RNAi therapies, and other novel modalities. Its differentiation lies in targeting DNA instability itself, a potentially upstream mechanism, rather than reducing expression of the mutant protein.